{"nctId":"NCT02918357","briefTitle":"Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence","startDateStruct":{"date":"2016-09-15","type":"ACTUAL"},"conditions":["Prostate Cancer"],"count":385,"armGroups":[{"label":"Ga-68 labeled PSMA-11 PET","type":"EXPERIMENTAL","interventionNames":["Drug: Ga-68 labeled PSMA-11 PET"]}],"interventions":[{"name":"Ga-68 labeled PSMA-11 PET","otherNames":["Ga-68 labeled DKFZ-PSMA-11","Ga-68 labeled Glu-NH-CO-NH- Lys(Ahx)-HBED-CC","Ga-68 labeled Glu-urea- Lys(Ahx)-HBED-CC","Ga-68 labeled HBED-CC PSMA"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histopathological proven prostate adenocarcinoma.\n* Rising prostate-specific antigen (PSA) after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy).\n\n  * Post radical prostatectomy (RP) - American Urological Association (AUA) recommendation\n\n    * PSA greater than 0.2 ng/mL measured more than 6 weeks after RP and,\n    * Confirmatory persistent PSA greater than 0.2 ng/mL\n  * Post-radiation therapy -ASTRO-Phoenix consensus definition\n\n    * Nadir + greater than or equal to 2 ng/mL rise in PSA\n* Karnofsky performance status of greater than 50 (or Eastern Cooperative Oncology Group (ECOG) /World Health Organization (WHO) equivalent).\n* Age \\> 18.\n* Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\n* Investigational therapy for prostate cancer.\n* Unable to lie flat, still or tolerate a PET scan.\n* Prior history of any other malignancy within the last 2 years, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer.\n* Contraindication to furosemide administration including prior allergy or adverse reaction to furosemide or sulfa drugs. (Note: This exclusion criteria can be removed if Furosemide is omitted as part of the PET imaging protocol if a second-generation scatter correction is available for the used PET device).","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation","description":"PPVs were calculated across the group on a per-patient basis on 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy and reported along with the corresponding two-sided 95% confidence intervals (CI). The CIs were constructed using the Wilson score method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.90","spread":null}]}]}]},{"type":"PRIMARY","title":"Positive Predictive Value (PPV) on a Per-region Basis With Histologic Validation","description":"PPVs were calculated across the group on a per-region-basis on 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy and reported along with the corresponding two-sided 95% CIs. The CIs were constructed using the Wilson score method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.91","spread":null}]}]}]},{"type":"SECONDARY","title":"PPVs on a Per-patient of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up","description":"PPVs on a per-patient basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by conventional imaging follow-up were calculated and reported along with the corresponding two-sided 95% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.81","spread":null}]}]}]},{"type":"SECONDARY","title":"PPVs on a Per-region of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up","description":"PPVs on a per-region-basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy and conventional imaging follow-up were calculated and reported along with the corresponding two-sided 95% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.92","spread":null}]}]}]},{"type":"SECONDARY","title":"Sensitivity on a Per-patient Basis","description":"Sensitivity, on a per-patient basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy was calculated. The 95% CI was calculated using the Wilson score method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.92","spread":null}]}]}]},{"type":"SECONDARY","title":"Sensitivity on a Per-region Basis","description":"Sensitivity, on a per-region basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy was calculated. The 95% CI was calculated using the Wilson score method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.90","spread":null}]}]}]},{"type":"SECONDARY","title":"Detection Rates of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value","description":"Detection rate was defined as proportion of 68Ga-PSMA-11 PET positive patients, independent of the reference standard stratified by PSA value (0.2-\\<0.5; 0.5-\\<1.0; 1.0-\\<2.0; 2.0-\\<5.0, and â‰¥5.0).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"51","spread":null},{"groupId":"OG002","value":"87","spread":null},{"groupId":"OG003","value":"83","spread":null},{"groupId":"OG004","value":"96","spread":null}]}]}]},{"type":"SECONDARY","title":"Inter-reader Agreement Per-region","description":"Inter-reader reproducibility for positivity at region level was reported using the Fleiss' Kappa test for multiple readers. Kappa value varies from 0 (no agreement) to 1 (perfect agreement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":null},{"groupId":"OG001","value":"0.73","spread":null},{"groupId":"OG002","value":"0.70","spread":null},{"groupId":"OG003","value":"0.78","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Change in Clinical Management","description":"Clinical management changes were assessed using surveys of Intended Management to determine the percent change in clinical management after 68Ga-PSMA-11 PET.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety Assessment - Heart Rate","description":"Patient vital signs were measured before and after 68Ga-PSMA-11 injections and absolute mean change was calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.8","spread":"13.3"},{"groupId":"OG001","value":"66.9","spread":"13.6"},{"groupId":"OG002","value":"0.9","spread":"11.2"}]}]}]},{"type":"SECONDARY","title":"Safety Assessment - Blood Pressure","description":"Patient vital signs were measured before and after 68Ga-PSMA-11 injections and absolute mean change was calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"137.8","spread":"17.7"},{"groupId":"OG001","value":"137.0","spread":"17.4"},{"groupId":"OG002","value":"1.0","spread":"18.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.3","spread":"33.8"},{"groupId":"OG001","value":"81.1","spread":"10.6"},{"groupId":"OG002","value":"0.6","spread":"34.0"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":385},"commonTop":[]}}}